Donate For Public and Patients Store Search

American Academy of Dermatology Logo

Measure 337

Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis on a Biological Immune Response Modifier

Description: The percentage of patients with psoriasis, psoriatic arthritis, and/or rheumatoid arthritis on a biological immune response modifier whose providers are ensuring active tuberculosis prevention.

Measure ID: 337

Type: Process

CMS Derm Specialty Set: Yes

Priority: No

Topped out: No

Reporting methods: Registry/QCDR

Maximum points: 10

Measure purpose: This measure encourages tuberculosis (TB) prevention for patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis on a biological immune response modifier. Physicians should ensure active TB prevention either through yearly negative standard TB screening tests or by reviewing the patient’s history to determine if they have had appropriate management for a recent or prior positive test.  


The numerator: The number of patients who have a documented negative annual TB screening or have documentation of the management of a positive TB screening test with no evidence of active tuberculosis, confirmed through use of radiographic imaging (i.e., chest x-ray, CT) 


The denominator: All patients with a diagnosis of psoriasis, psoriatic arthritis, and/or rheumatoid arthritis who are on a biologic immune response modifier.

Measure calculation example

Dr. Lynch saw 42 patients during the reporting period who have psoriasis, psoriatic arthritis, rheumatoid arthritis, or any combination of the three. This is the denominator. Of the 42 patients, Dr. Lynch documented a negative annual TB screening 25 times. This is the numerator.

Quality of patient care = 25/42. Dr. Lynch has a score of 59.5% for this measure. This translates to 3.0 to 3.9 points.

Important note

Because of how this measure is structured, physicians score 3 points even if they report on only one patient. Physicians receive no additional score for reporting scores that fall below 47.06%. For example, if Dr. Lynch reported on one patient encounter, he would earn 3 points. A score of 99.9% earns 8.9 points, while a score of 100% earns 10 points. In effect, there is a gap in earned points between a nearly perfect score and a perfect score.

Examples of applicable medications to MIPS 337

Brand nameChemical nameMechanism of action/Type of biologic
 Orencia  Abatacept  Blocks T cell activation
 Rituxan  Rituximab  CD 20 directed antibody
 Kineret  Anakinra  IL1 inhibitors
 Stelara  Ustekinumab  IL-12 and IL-23 inhibitors
 Cosentyx  Secukinumab  IL-17 inhibitors
 Siliq  Brodalumab  IL-17 inhibitors
 Taltz  Ixekizumab  IL-17 inhibitors
 Tremfya  Guselkumab  IL-23 inhibitors
 Actemra  Tocilizumab  IL-6 inhibitor
 Kevzara  Sarilumab  IL-6 inhibitor
 Amjevita  Adalimumab-atto  TNF-alpha inhibitors
 Cimzia  Certolizumab  TNF-alpha inhibitors
 Cyltezo  Adalimumab-adbm  TNF-alpha inhibitors
 Enbrel  Etanercept  TNF-alpha inhibitors
 Erelzi  Etanercept-szzs  TNF-alpha inhibitors
 Humira  Adalimumab  TNF-alpha inhibitors
 Inflectra  Infliximab-dyyb  TNF-alpha inhibitors
 Remicade  Infliximab  TNF-alpha inhibitors
 Renflexis  Infliximab-abda  TNF-alpha inhibitors
 Simponi &
 Simponi Aria
 Golimumab  TNF-alpha inhibitors

Click on the image to download PDF.

Quality measure score benchmark

CMS will award points based on a comparison of your performance rate to CMS benchmarks listed below. Reach the performance rate listed to achieve the corresponding points per measure. The maximum points you can achieve for the quality score is 45 points.

Below 3 Decile 3Decile 4Decile 5Decile 6Decile 7Decile 8Decile 9Decile 10 
Performance rate  1 patient  47.06 - 
 60.61 - 
73.63 - 
82.51 - 
90.00 - 
 96.43 - 99.99 --  100% 
Points  3 points  3 - 3.9  4 - 4.9 5 - 5.9 6 - 6.9 7 - 7.9 8 - 8.9 9 - 9.9 10